SEC Form 4 · accession 0001209191-18-057056
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly Manhard
Officer — Executive VP, Drug Development
Period of report
Nov 2, 2018
Accepted (ET)
Nov 2, 2018 · 9:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 31, 2018 | J | 494 | $23.596 | A | 494 | D | |
| Common StockF3 | Nov 2, 2018 | S | 494 | $30.6173 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2018.
- F2The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018.
- F3The range of sales prices received was $30.34 to $30.89. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.